^
    Apply
    Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial (NCT05554380)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/22/2023
    Primary completion :
    08/31/2025
    Completion :
    08/31/2025
    AKT2
    |
    AKT1 mutation
    |
    paclitaxel • ipatasertib (RG7440)
    Testing ONC201 to Prevent Colorectal Cancer (NCT05630794)
    Phase 1
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    02/21/2025
    Initiation :
    03/30/2025
    Primary completion :
    01/01/2026
    Completion :
    01/01/2028
    BCL2 • IL6 • TNFA • IL10 • CASP3 • GZMA • IL17A • PRL
    |
    Modeyso (dordaviprone)
    Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers (NRG-GY028) (NCT05538897)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    03/31/2023
    Primary completion :
    01/31/2027
    Completion :
    01/31/2027
    AKT1S1
    |
    ipatasertib (RG7440) • megestrol
    Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia (NCT05881265)
    Phase 2
    Shanghai Jiao Tong University School of Medicine
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    05/15/2023
    Primary completion :
    01/01/2026
    Completion :
    01/01/2026
    RARA • PML
    |
    Venclexta (venetoclax) • Epidaza (chidamide)
    Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (NCI-2021-13902) (NCT05172258)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    07/26/2022
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    PD-L1
    |
    Keytruda (pembrolizumab) • ipatasertib (RG7440) • Pembroria (pembrolizumab biosimilar)
    Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer (NRG-GY027) (NCT05276973)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    09/08/2022
    Primary completion :
    01/30/2025
    Completion :
    01/30/2025
    PTEN • HRD • NF1 • AKT1 • TSC1 • AKT1S1
    |
    HRD
    |
    carboplatin • paclitaxel • ipatasertib (RG7440)
    Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... (NCT02390752)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    04/29/2015
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    NF1
    |
    Turalio (pexidartinib)
    Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma (NCT05958719)
    Phase 2
    Institute of Hematology & Blood Diseases Hospit...
    Recruiting
    Last update posted :
    12/30/2024
    Initiation :
    03/02/2023
    Primary completion :
    12/30/2026
    Completion :
    03/02/2027
    IFNG • IL6 • TNFA • IL10 • IFNA1
    |
    azacitidine • prednisone • Epidaza (chidamide) • Duoenda (mitoxantrone liposomal)
    Comparison of VA (Venetoclax, Azacitidine), VACl (VA, Cladribine), VACh (VA, Chidamide), and Alternating VACl/VACh in Newly Diagnosed Acute Myeloid Leukemia (NCT06532552)
    Phase 2
    The First Affiliated Hospital of Soochow Univer...
    Recruiting
    Last update posted :
    11/20/2024
    Initiation :
    07/29/2024
    Primary completion :
    08/01/2027
    Completion :
    08/01/2028
    BCL2
    |
    Venclexta (venetoclax) • azacitidine • Epidaza (chidamide) • cladribine
    Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor Lymphoma (DEL Biomarker) (NCT06652152)
    Phase N/A
    Ruijin Hospital
    Not yet recruiting
    Last update posted :
    10/22/2024
    Initiation :
    10/30/2024
    Primary completion :
    05/30/2025
    Completion :
    12/30/2025
    BCL2
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Epidaza (chidamide)
    Trial of Olaparib in Combination with AZD5363 (ComPAKT) (NCT02338622)
    Phase 1
    Royal Marsden NHS Foundation Trust
    Completed
    Last update posted :
    09/26/2024
    Initiation :
    03/31/2014
    Primary completion :
    03/21/2016
    Completion :
    03/21/2017
    BRCA1 • BRCA2 • PARP1
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • Truqap (capivasertib)
    Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant. (NCT06563778)
    Phase 2
    Chinese PLA General Hospital
    Not yet recruiting
    Last update posted :
    08/21/2024
    Initiation :
    09/01/2024
    Primary completion :
    09/01/2026
    Completion :
    09/01/2028
    PD-1
    |
    decitabine • Adcetris (brentuximab vedotin) • Epidaza (chidamide) • bendamustine